University Hospital Heidelberg
2022 - Research.com Rising Star of Science Award
His primary areas of study are Cancer research, Pathology, IDH1, Astrocytoma and IDH2. His study in Oligodendroglioma and Glioma are all subfields of Cancer research. He combines subjects such as Exome sequencing, V600E and Solitary fibrous tumor with his study of Pathology.
Felix Sahm works mostly in the field of IDH1, limiting it down to topics relating to ATRX and, in certain cases, Brain tumor, Pilocytic astrocytoma, Neuropathology and DNA sequencing. As a member of one scientific family, Felix Sahm mostly works in the field of Astrocytoma, focusing on Immunohistochemistry and, on occasion, Monoclonal. His research in IDH2 intersects with topics in Medulloblastoma and 1p/19q Codeletion.
Felix Sahm mainly investigates Cancer research, Pathology, DNA methylation, Glioma and Internal medicine. In his study, which falls under the umbrella issue of Cancer research, Oligodendroglioma is strongly linked to IDH1. In his research on the topic of Pathology, ATRX is strongly related with Astrocytoma.
His research investigates the connection between DNA methylation and topics such as Epigenetics that intersect with issues in Medulloblastoma. Glioma and Isocitrate dehydrogenase are two areas of study in which he engages in interdisciplinary work. In his study, Temozolomide, Radiation therapy, Clinical trial and Glioblastoma is inextricably linked to Oncology, which falls within the broad field of Internal medicine.
His main research concerns DNA methylation, Cancer research, Pathology, Meningioma and Methylation. His DNA methylation research incorporates elements of Oncology, Internal medicine, Uterus, Mutation and CDKN2A. His is doing research in Glioma and Astrocytoma, both of which are found in Cancer research.
The Pathology study combines topics in areas such as Choroid plexus papilloma, Fusion transcript and Oligodendroglioma. His Meningioma study combines topics from a wide range of disciplines, such as Immunohistochemistry, Clinicopathological features, Who classification, Brain tumor and Hazard ratio. His studies deal with areas such as Somatic cell, Fusion gene, Subclass, Pilocytic astrocytoma and Sarcoma as well as Methylation.
Glioma, Cancer research, Cell biology, DNA methylation and Astrocytoma are his primary areas of study. His Glioma research includes themes of Niche, Missense mutation, H3 K27M Mutation, Epidermal growth factor receptor and IDH1. His Cancer research research is multidisciplinary, incorporating elements of DNA damage, Mutation, ATRX, MSH2 and EGFR Gene Amplification.
The various areas that Felix Sahm examines in his Cell biology study include Cell culture, Downregulation and upregulation, Multicellular organism, Receptor and Cytotoxic T cell. His DNA methylation research is multidisciplinary, incorporating perspectives in Methylation and Sarcoma, Pathology. His Astrocytoma research integrates issues from MLH1, MSH6, Germline mutation and DNA mismatch repair.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Brain tumour cells interconnect to a functional and resistant network
Matthias Osswald;Matthias Osswald;Erik Jung;Erik Jung;Felix Sahm;Felix Sahm;Gergely Solecki;Gergely Solecki.
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher;Lukas Bunse;Stefan Pusch;Felix Sahm.
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm;Dominik Sturm;Brent A. Orr;Umut H. Toprak;Volker Hovestadt.
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche;Frédéric Charlotte;Laurent Arnaud;Andreas von Deimling.
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn.
The New England Journal of Medicine (2017)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
David Capper;David Capper;Matthias Preusser;Matthias Preusser;Antje Habel;Felix Sahm;Felix Sahm.
Acta Neuropathologica (2011)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
David E. Reuss;Felix Sahm;Felix Sahm;Daniel Schrimpf;Daniel Schrimpf;Benedikt Wiestler;Benedikt Wiestler.
Acta Neuropathologica (2015)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm;Felix Sahm;Daniel Schrimpf;Damian Stichel;David T.W. Jones.
Lancet Oncology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: